The epilepsy therapeutic market in APAC share is expected to increase by USD 296.44 million from 2020 to 2025, and the market’s growth momentum will accelerate at a CAGR of 4.01%.
This epilepsy therapeutic market in the APAC research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers the epilepsy therapeutics market in APAC segmentations by product (first-generation epilepsy therapeutic, second-generation epilepsy therapeutic, and third-generation epilepsy therapeutic) and geography (Asia and the Rest of APAC). The epilepsy therapeutics market in the APAC report also offers information on several market vendors, including Bausch Health Companies Inc., BIAL - PORTELA & CA SA, GlaxoSmithKline Plc, Johnson & Johnson Services, Inc., Novartis AG, Pfizer Inc., SanofiSA, Sunovion Pharmaceuticals Inc., UCB SA, and Zogenix Inc. among others.
What will the Epilepsy therapeutic Market In APAC Size be During the Forecast Period?
Download Report Sample to Unlock the Epilepsy therapeutics Market in APAC Size for the Forecast Period and Other Important Statistics
Epilepsy Therapeutics Market In APAC: Key Drivers, Trends, and Challenges
The increase in the patient population is notably driving the epilepsy therapeutics market in APAC growth, although factors such as generic erosion may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the epilepsy therapeutics market in the APAC. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Epilepsy Therapeutics Market In APAC Driver
An increase in the patient population is one of the major drivers of the epilepsy therapeutics market growth in the APAC. The annual incidence rate of epilepsy in developed countries is approximately 45-55 per 100,000 individuals, with higher rates in infants and older populations. In developing countries, the incidence rate is almost double, reaching about 95-105 per 100,000 individuals annually. The prevalence rate of epilepsy in developed countries is estimated between 5-10 per 1,000 individuals annually, whereas this rate is much higher in developing countries, reaching approximately 125-135 individuals annually. The developing countries witness high incidence and prevalence rates due to the increasing population, and the lack of proper diagnostic tools refraining from detecting the early symptoms of epilepsy. The increase in the patient population is expected to increase the consumption of AEDs, thereby driving market growth.
Key Epilepsy Therapeutics Market In APAC Trend
The emergence of new-generation AEDs is one of the major trends in the epilepsy therapeutics market growth in the APAC. The epilepsy therapeutics market in APAC is currently witnessing a shift in focus toward second-generation AEDs. These drugs offer various advantages over first-generation AEDs such as simpler pharmacokinetic profiles. Japan is anticipated to experience a major shift in the trend toward second-generation drugs because of the recent launch of these drugs in the Japanese market. However, various territories in the APAC region are still dominated by first-generation AEDs. Market stratification of major vendors to penetrate the countries in APAC and increasing healthcare reforms are expected to change the epilepsy treatment regimen. Third-generation AEDs such as VIMPAT (lacosamide) is also fueling the growth of the market.
Key Epilepsy Therapeutics Market In APAC Challenge
Generic erosion is one of the major challenges to the epilepsy therapeutics market growth in the APAC. Patent expiry of a drug often results in the loss of an exclusive market for that drug, leading to a rapid decline in sales. For instance, LYRICA lost its exclusivity in 2019. As a result, the revenue of LYRICA in Canada and the EU decreased significantly. Similarly, the loss of exclusivity in APAC is anticipated to negatively impact the epilepsy therapeutics market in APAC. Since April 2009, Pfizer has filed lawsuits in the US District Court for the District of Delaware against generic manufacturers who have filed Abbreviated New Drug Applications (ANDAs) for LYRICA. Therefore, generic manufacturers for LYRICA could not obtain US FDA approval until LYRICA's basic patent expired in 2018. The regulatory exclusivity for LYRICA was valid until 2014 in the EU. In July 2013, UCB filed lawsuits against generic manufacturers such as Mylan, Sun Pharma, Ranbaxy, and Aurobindo Pharma for overfilling of ANDA for VIMPAT. Once these generics are launched in developed countries, they reach APAC within 6-9 months from their launch. Such instances are anticipated to negatively impact the market in APAC during the forecast period.
This epilepsy therapeutics market in the APAC analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.
Parent Market Analysis
Technavio categorizes the epilepsy market in APAC 2021-2025 as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the epilepsy therapeutics market in APAC during the forecast period.
Who are the Major Epilepsy Therapeutics Market In APAC Vendors?
The report analyzes the market’s competitive landscape and offers information on several market vendors, including:
- Bausch Health Companies Inc.
- BIAL - PORTELA & CA SA
- GlaxoSmithKline Plc
- Johnson & Johnson Services, Inc.
- Novartis AG
- Pfizer Inc.
- Sunovion Pharmaceuticals Inc.
- UCB SA
- Zogenix Inc.
This statistical study of the epilepsy therapeutics market in APAC encompasses successful business strategies deployed by the key vendors. The epilepsy therapeutics market in APAC is fragmented and the vendors are deploying various organic and inorganic growth strategies to compete in the market.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The epilepsy therapeutics market in the APAC forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Epilepsy Therapeutics Market In APAC Value Chain Analysis
Our report provides extensive information on the value chain analysis for the epilepsy therapeutics market in APAC, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
The value chain of the pharmaceuticals market includes the following core components:
- Inbound logistics
- Outbound logistics
- Marketing and sales
- Support activities
The report has further elucidated other innovative approaches being followed by manufacturers to ensure a sustainable market presence.
Which are the Key Regions for Epilepsy Therapeutics Market In APAC?
For more insights on the market share of various regions Request PDF Sample now!
76% of the market’s growth will originate from Asia during the forecast period. Japan, China, India, Australia, and South Korea (Republic of Korea) are the key markets for the epilepsy therapeutics market in APAC in Asia. Market growth in this region will be faster than the growth of the market in regions.
The rise in the incidence rate of epilepsy will facilitate the epilepsy therapeutics market growth in Asia over the forecast period. To garner further competitive intelligence and regional opportunities in store for vendors, view our sample report.
What are the Revenue-generating Product Segments in the Epilepsy therapeutics Market In APAC?
To gain further insights on the market contribution of various segments Request PDF Sample
The epilepsy therapeutics market share growth in APAC by the first-generation epilepsy therapeutics segment will be significant during the forecast period. The first-generation AEDs include benzodiazepines, carbamazepine, phenytoin, valproic acid, and phenobarbital. These drugs usually require close monitoring and often lead to life-threatening reactions.
This report provides an accurate prediction of the contribution of all the segments to the growth of the epilepsy therapeutics market in APAC size and actionable market insights on post COVID-19 impact on each segment.
Epilepsy therapeutics Market In APAC Scope
Growth momentum & CAGR
Accelerate at a CAGR of 4.01%
Market growth 2021-2025
$ 296.44 million
YoY growth (%)
Asia and Rest of APAC
Performing market contribution
Asia at 76%
Key consumer countries
Japan, China, India, Australia, and South Korea (Republic of Korea)
Leading companies, Competitive strategies, Consumer engagement scope
Key companies profiled
Bausch Health Companies Inc., BIAL - PORTELA & CA SA, GlaxoSmithKline Plc, Johnson & Johnson Services, Inc., Novartis AG, Pfizer Inc., SanofiSA, Sunovion Pharmaceuticals Inc., UCB SA, and Zogenix Inc.
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.
Request PDF sample
What are the Key Data Covered in this Epilepsy therapeutics Market In APAC In Regional Report?
- CAGR of the market during the forecast period 2021-2025
- Detailed information on factors that will drive epilepsy therapeutics market in APAC growth during the next five years
- Precise estimation of the epilepsy therapeutics market in APAC size and its contribution to the parent market
- Accurate predictions on upcoming trends and changes in consumer behavior
- The growth of the epilepsy therapeutics market in APAC industry across Asia and Rest of APAC
- A thorough analysis of the market’s competitive landscape and detailed information on vendors
- Comprehensive details of factors that will challenge the growth of epilepsy therapeutics market in APAC vendors
We can help! Our analysts can customize this report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
- 3.1 Market definition
- Exhibit 07: Epilepsy market in APAC: Year-over-year growth 2020 - 2025 (%)
- 3.2 Market segment analysis
- 3.4 Market outlook: Forecast for 2020 - 2025
4 Five Forces Analysis
- 4.1 Five forces summary
- Exhibit 14: Market condition - Five forces 2020
- 4.2 Bargaining power of buyers
- 4.3 Bargaining power of suppliers
- 4.4 Threat of new entrants
- 4.5 Threat of substitutes
5 Market Segmentation by Product
- 5.2 Comparison by Product
- 5.3 First-generation epilepsy therapeutics - Market size and forecast 2020-2025
- 5.4 Second-generation epilepsy therapeutics - Market size and forecast 2020-2025
- 5.5 Third-generation epilepsy therapeutics - Market size and forecast 2020-2025
- 5.6 Market opportunity by Product
6 Customer landscape
7 Geographic Landscape
- 7.1 Geographic segmentation
- 7.2 Geographic comparison
- 7.3 Asia - Market size and forecast 2020-2025
- 7.4 Rest of APAC - Market size and forecast 2020-2025
- 7.5 Key leading countries
- 7.6 Market opportunity by geography
8 Drivers, Challenges, and Trends
9 Drivers, Challenges, and Trends
10 Vendor Landscape
- 10.1 Overview
- Exhibit 76: UCB SA - Overview
- Exhibit 77: UCB SA - Product and service
- 10.2 Vendor landscape
- Exhibit 78: UCB SA - Key news
- Exhibit 79: UCB SA - Key offerings
- 10.3 Landscape disruption
- Exhibit 80: Zogenix Inc. - Overview
- Exhibit 81: Zogenix Inc. - Product and service
- Exhibit 82: Zogenix Inc. - Key news
- Exhibit 83: Zogenix Inc. - Key offerings
11 Vendor Analysis
- 11.1 Vendors covered
- Exhibit 84: Currency conversion rates for US$
- 11.2 Market positioning of vendors
- Exhibit 85: Research Methodology
- 11.3 Bausch Health Companies Inc.
- Exhibit 86: Validation techniques employed for market sizing
- Exhibit 87: Information sources
- Exhibit 88: List of abbreviations
- 11.4 BIAL - PORTELA & CA SA
- 11.6 Johnson & Johnson Services, Inc.
- 11.10 Sunovion Pharmaceuticals Inc.
- 12.2 Currency conversion rates for US$
- 12.3 Research methodology
- 12.4 List of abbreviations